checkAd
    Startseite > Aktien > Mesoblast > Nachrichten
    Mesoblast Aktie
    7,4400
     
    USD
    -1,46 %
    -0,1100 USD
    Letzter Kurs 02:00:00 Nasdaq
    7,4200
     
    USD
    100 STK
    Geldkurs 31.05.24
    7,4500
     
    USD
    1.500 STK
    Briefkurs 31.05.24
    ISIN: US5907174016 · WKN: A4004R · SYM: MESO · Australien

    Neueste Nachrichten

    United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor (Rexlemestrocel-L) in Children With Congenital Heart Disease
    19.01.24 · globenewswire · Mesoblast
    Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease
    27.11.23 · globenewswire · Mesoblast
    Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD
    22.11.23 · globenewswire · Mesoblast
    Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023
    31.10.23 · globenewswire · Mesoblast
    Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee
    26.09.23 · globenewswire · Mesoblast
    Key Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL Approval
    21.09.23 · globenewswire · Mesoblast
    Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023
    31.08.23 · globenewswire · Mesoblast
    Mesoblast Financial Results and Corporate Update Webcast
    29.08.23 · globenewswire · Mesoblast
    Mesoblast Receives Complete Response From U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children
    04.08.23 · globenewswire · Mesoblast
    Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2023
    31.07.23 · globenewswire · Mesoblast
    Mesoblast Director Philip R. Krause, M.D., Appointed to Strategic Advisory Role
    05.06.23 · globenewswire · Mesoblast